arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Abbott Laboratories

ABT Health Care Biotechnology: Pharmaceutical Preparations
$102.51
▲ +0.1% Today
as of Oct 22, 16:45 ET
Last 30 days -0.56% Sep 14 → Oct 22
$96.03 $98.41 $100.79 $103.17 $105.55 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$101.50
High
$102.90
Low
$99.95
Volume
$11M
Avg Vol
$10M
Mkt Cap
$170.8B
P/E (TTM)
40.97
Beta
—
52w High
$132.03
52w Low
$81.97
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 0 ● 24 ▼ 1
Oct 22 · 09:54 MT Newswires neutral
Wells Fargo Adjusts Price Target on Abbott Laboratories to $119 From $112
Oct 22 · 09:54 MT Newswires neutral
Leerink Partners Adjusts Price Target on Abbott Laboratories to $106 From $109
Oct 22 · 09:54 MT Newswires neutral
BTIG Adjusts Price Target on Abbott Laboratories to $125 From $134
▸ Show all 25 press releases & news Free account →

ABT earnings at a glance

The options market is pricing a move of about ±5.7% after the report, a range of roughly $96.68 to $108.34 from today's $102.51. Over its last 5 reports the stock rose the next day 1 time and fell 4, moving ±7.6% on average; after the most recent report on Jul 16, 2026 it moved +10.7%. That means options currently expect less movement than ABT has typically delivered. ABT beat the consensus EPS estimate in 3 of its last 5 reported quarters. Implied volatility is currently 35%. The share price of $102.51 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$82
$132
41% of range
Avg surprise (last 5)
+0.8%
Avg reaction (last 5)
-3.3%
20% positive
Latest IV / EM
35%
EM ±5.7% · $98 · Oct 23

Earnings trends

EPS — actual vs estimate Actual Estimate
$0.70$0.90$1.10$1.30$1.50 Actual $0.75Actual $0.78Actual $0.82Actual $0.70Actual $0.74Actual $0.94Actual $0.76Actual $1.26Est $1.25Actual $1.30Est $1.30Actual $1.50Est $1.50Actual $1.15Est $1.14Actual $1.31Est $1.28 MarJunSepMarJunSepMarJun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$0$3.0B$6.0B$9.0B$11.9B Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Jul 16, 2026Jun/2026 $1.31 $1.28 +2.3% +1.6% +10.7% earnings
Thu Apr 16, 20268K 2026-04-16 $1.15 $1.14 +0.9% — -6.0% earnings
Thu Jan 22, 20268K 2026-01-22 $1.50 $1.50 0.0% — -10.0% earnings
Wed Oct 15, 2025Sep/2025 $1.30 $1.30 0.0% — -2.9% earnings
Thu Jul 17, 2025Jun/2025 $1.26 $1.25 +0.8% — -8.5% earnings
Mon Mar 31, 2025Mar 2025 $0.76 — — — — financials
Mon Sep 30, 2024Sep 2024 $0.94 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.74 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.70 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.82 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.78 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.75 — — — — financials
Fri Sep 30, 2022Sep 2022 $0.81 — — — — financials

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue$11.16B—$11.37B$11.14B$10.36B—$10.63B$10.38B
Cost of revenue$4.89B—$5.08B$4.85B$4.47B—$4.70B$4.60B
Gross profit————————
Operating income$1.34B—$2.06B$2.05B$1.69B—$1.86B$1.67B
Net income$1.08B—$1.64B$1.78B$1.32B—$1.65B$1.30B
EPS (diluted)$0.61—$0.94$1.01$0.76—$0.94$0.74

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$6.80B$8.52B$7.51B$6.95B$6.53B$7.62B$7.56B$6.99B
Inventory$6.99B$6.49B$6.71B$6.95B$6.64B$6.19B$6.81B$6.81B
Total current assets$25.51B$26.00B$24.84B$24.47B$23.15B$23.66B$23.80B$23.12B
Total assets$110.43B$86.71B$84.18B$84.00B$81.45B$81.41B$74.36B$73.02B
Long-term debt$29.64B$9.90B$11.60B$12.93B$12.74B$12.62B$12.82B$13.14B
Total liabilities————————
Total equity$52.06B$52.13B$50.95B$50.56B$48.81B$47.66B$39.80B$39.32B

Implied volatility — last 90 days

23%38%54%70%85% Jun 07 — IV 38% · EM ±3.6%Jun 08 — IV 32% · EM ±2.7%Jun 09 — IV 40% · EM ±2.9%Jun 10 — IV 28% · EM ±1.6%Jun 11 — IV 47% · EM ±2.0%Jun 15 — IV 26% · EM ±1.9%Jun 16 — IV 36% · EM ±2.2%Jun 17 — IV 37% · EM ±1.6%Jun 19 — IV 30% · EM ±3.3%Jun 22 — IV 34% · EM ±2.8%Jun 23 — IV 32% · EM ±2.3%Jun 24 — IV 36% · EM ±2.1%Jun 25 — IV 32% · EM ±1.3%Jun 29 — IV 38% · EM ±6.8%Jun 30 — IV 39% · EM ±6.6%Jul 01 — IV 38% · EM ±6.3%Jul 02 — IV 42% · EM ±6.7%Jul 03 — IV 43% · EM ±6.7%Jul 06 — IV 46% · EM ±6.4%Jul 07 — IV 46% · EM ±6.1%Jul 08 — IV 53% · EM ±6.6%Jul 09 — IV 48% · EM ±5.6%Jul 10 — IV 49% · EM ±5.4%Jul 13 — IV 65% · EM ±5.4%Jul 14 — IV 73% · EM ±5.3%Jul 15 — IV 86% · EM ±5.1%Jul 16 — IV 44% · EM ±1.8%Jul 20 — IV 33% · EM ±2.8%Jul 21 — IV 34% · EM ±2.5%Jul 22 — IV 33% · EM ±2.0%Jul 23 — IV 42% · EM ±1.7%Jul 27 — IV 34% · EM ±2.8%Jul 28 — IV 33% · EM ±2.4%Jul 29 — IV 31% · EM ±1.8%Jul 30 — IV 41% · EM ±1.7%Aug 03 — IV 32% · EM ±2.7%Aug 04 — IV 47% · EM ±3.4%Aug 05 — IV 42% · EM ±2.5%Aug 06 — IV 30% · EM ±1.3%Aug 10 — IV 27% · EM ±2.2%Aug 11 — IV 24% · EM ±1.7%Aug 12 — IV 26% · EM ±1.6%Aug 13 — IV 24% · EM ±1.0%Aug 17 — IV 23% · EM ±1.9%Aug 18 — IV 24% · EM ±1.7%Aug 19 — IV 26% · EM ±1.6%Aug 20 — IV 39% · EM ±1.6%Aug 24 — IV 24% · EM ±2.0%Aug 25 — IV 27% · EM ±2.0%Aug 26 — IV 28% · EM ±1.6%Aug 27 — IV 31% · EM ±1.3%Aug 31 — IV 39% · EM ±3.3%Sep 01 — IV 28% · EM ±2.0%Sep 02 — IV 31% · EM ±1.8%Sep 03 — IV 34% · EM ±1.4%Sep 07 — IV 33% · EM ±2.7%Sep 08 — IV 31% · EM ±2.2%Sep 09 — IV 35% · EM ±2.0%Sep 10 — IV 31% · EM ±1.3%Sep 14 — IV 26% · EM ±2.1%Sep 15 — IV 33% · EM ±2.4%Sep 16 — IV 26% · EM ±1.5%Sep 17 — IV 32% · EM ±1.3%Sep 21 — IV 28% · EM ±2.4%Sep 22 — IV 29% · EM ±2.1%Sep 23 — IV 32% · EM ±1.9%Sep 24 — IV 31% · EM ±1.3%Sep 28 — IV 36% · EM ±7.5%Sep 29 — IV 35% · EM ±7.1%Sep 30 — IV 33% · EM ±6.6%Oct 01 — IV 37% · EM ±7.2%Oct 02 — IV 36% · EM ±6.9%Oct 05 — IV 31% · EM ±5.5%Oct 06 — IV 36% · EM ±6.2%Oct 07 — IV 38% · EM ±6.3%Oct 08 — IV 35% · EM ±5.7%

Sector peers

NVO
Novo Nordisk A/S
$169.4B $39.43+0.2%
VRTX
Vertex Pharmaceuticals Incorporated
$128.2B $535.17+4.0%
SNY
Sanofi
$98.0B $41.96+1.4%
REGN
Regeneron Pharmaceuticals, Inc.
$76.4B $819.09+1.4%
NVS
Novartis AG
$273.4B $156.27+1.7%
TEVA
Teva Pharmaceutical Industries Limited
$45.7B $40.21-1.6%

ABT earnings FAQ

What is ABT's expected move for earnings?

Options currently price a move of about ±5.7%, or $5.83 per share either way from $102.51.

How does ABT stock usually react to earnings?

Across the last 5 reports the average next-day move was ±7.6%, up 1 times and down 4 times.

What is ABT's implied volatility?

ABT's at-the-money implied volatility is about 35% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in